Research progress on the heterogeneity of anti-vascular endothelial growth factor therapy response in diabetic macular edema

doi:10.11958/20253432

Abstract

Abstract:

Diabetic retinopathy (DR) is one of the common ocular complications in diabetic patients, which can cause severe impairment of visual function. Among DR patients, diabetic macular edema (DME) is the most common cause of central vision impairment. Anti-vascular endothelial growth factor (VEGF) therapy is currently the first-line treatment for DME. However, anti-VEGF therapy shows significant heterogenelty in treatment response, suggesting that ocular or systemic factors may be involved. At present, the analysis of relevant influencing factors has not been fully elucidated. This article reviews the ocular and systemic factors that contribute to the heterogeneous response to anti-VEGF treatment in DME patients.

Key words: diabetic retinopathy, macular edema, tomography, optical coherence, vascular endothelial growth factors, treatment response

CLC Number:

R774.5，R587.2

References 46

[1]	Dervis N, Jurja S, Chisnoiu T, et al. Serum vitamin D levels as predictors of response to intravitreal anti-VEGF therapy in diabetic macular edema:A clinical correlation study[J]. Int J Mol Sci, 2025, 26(17):8481. doi:10.3390/ijms26178481.
[2]	Yan A, Jones C, Demirel S, et al. Diabetic macular edema:Upcoming therapies[J]. Graefes Arch Clin Exp Ophthalmol, 2025, 263(2):249-258. doi:10.1007/s00417-024-06595-7.
[3]	Chen K Y, Chan H C, Chan C M. Which treatment modality offers the best outcomes for diabetic retinopathy? A systematic review and network meta-analysis[J]. Diabetes Res Clin Pract, 2025, 227:112379. doi:10.1016/j.diabres.2025.112379.
[4]	Cheema A A, Cheema H R. Diabetic macular edema management:A review of anti-vascular endothelial growth factor(VEGF)therapies[J]. Cureus, 2024, 16(1):e52676. doi:10.7759/cureus.52676.
[5]	Chen Y P, Wu A L, Chuang C C, et al. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab:comparison between responder and non-responder cases[J]. Sci Rep, 2019, 9(1):10952. doi:10.1038/s41598-019-47241-1.
[6]	Liu D, Maguire M G, Jonna G, et al. Association of patient age with response to anti-vascular endothelial growth factor agents for treatment of diabetic macular edema[J]. Retina, 2025. doi:10.1097/IAE.0000000000004707.[Online ahead of print].
[7]	Sophie R, Lu N, Campochiaro P A. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab[J]. Ophthalmology, 2015, 122(7):1395-1401. doi:10.1016/j.ophtha.2015.02.036.
[8]	Gurung R L, Fitzgerald L M, Liu E, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice[J]. Int J Retina Vitreous, 2023, 9(1):23. doi:10.1186/s40942-023-00453-0.
[9]	Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants:long-term benefit in patients with chronic diabetic macular edema[J]. Ophthalmology, 2014, 121(10):1892-1903. doi:10.1016/j.ophtha.2014.04.019.
[10]	黄玥, 沈碧波, 赵东升. 糖尿病黄斑水肿对抗VEGF药物治疗的不同反应与糖尿病视网膜病变程度的相关性[J]. 国际眼科杂志, 2017, 17(2):348-350.
	Huang Y, Shen B B, Zhao D S. Correlation between responses to intravitreal injection of anti-VEGF and diabetic retinopathy extent in diabetic macular edema patients[J]. Int Eye Sci, 2017, 17(2):348-350.
[11]	Jakobsen T S, Adsersen R L, Askou A L, et al. Functional roles of pigment epithelium-derived factor in retinal degenerative and vascular disorders:A scoping review[J]. Invest Ophthalmol Vis Sci, 2024, 65(14):41. doi:10.1167/iovs.65.14.41.
[12]	Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology:vasogenic versus inflammatory[J]. J Diabetes Res, 2016, 2016:2156273. doi:10.1155/2016/2156273.
[13]	Liu X, Chen H H, Zhang L W. Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy[J]. Int J Ophthalmol, 2013, 6(2):221-227. doi:10.3980/J.ISSN.2222-3959.2013.02.22.
[14]	Gu W, Wang M, Li Z, et al. The association between peripheral blood inflammatory markers and anti-VEGF treatment response in patients with type 2 diabetic macular edema[J]. Front Med(Lausanne), 2025, 12:1653753. doi:10.3389/fmed.2025.1653753.
[15]	Katić K, Katić J, Kumrić M, et al. The predictors of early treatment effectiveness of intravitreal bevacizumab application in patients with diabetic macular edema[J]. Diagnostics(Basel), 2024, 14(10):992. doi:10.3390/diagnostics14100992.
[16]	Ergin E, Dascalu A M, Stana D, et al. Predictive role of complete blood count-derived inflammation indices and optical coherence tomography biomarkers for early response to intravitreal anti-VEGF in diabetic macular edema[J]. Biomedicines, 2025, 13(6):1308. doi:10.3390/biomedicines13061308.
[17]	González P, Lozano P, Ros G, et al. Hyperglycemia and oxidative stress:An integral,updated and critical overview of their metabolic interconnections[J]. Int J Mol Sci, 2023, 24(11):9352. doi:10.3390/ijms24119352.
[18]	Dagher C, Akiki M, Saliby R, et al. The impact of glycemic control on ranibizumab efficacy in diabetic retinopathy:A retrospective analysis[J]. Cureus, 2025, 17(1):e77124. doi:10.7759/cureus.77124.
[19]	Debourdeau E, Medard R, Chamard C, et al. Does HbA1c level or glomerular filtration rate affect the clinical response to endothelial growth factor therapy(Ranibizumab or Aflibercept)in diabetic macular edema? A real-life experience[J]. Ophthalmol Ther, 2023, 12(5):2657-2670. doi:10.1007/s40123-023-00758-1.
[20]	Gomez-Peralta F, Choudhary P, Cosson E, et al. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin[J]. Diabetes Obes Metab, 2022, 24(4):599-608. doi:10.1111/dom.14638.
[21]	Giacco F, Brownlee M. Oxidative stress and diabetic complications[J]. Circ Res, 2010, 107(9):1058-1070. doi:10.1161/CIRCRESAHA.110.223545.
[22]	Bressler S B, Qin H, Beck R W, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab[J]. Arch Ophthalmol, 2012, 130(9):1153-1161. doi:10.1001/archophthalmol.2012.1107.
[23]	Wang X N, Cai X, He S, et al. Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation[J]. Int Ophthalmol, 2023, 43(12):4399-4407. doi:10.1007/s10792-021-01806-0.
[24]	张怡, 姚静, 权彦龙, 等. 基于光学相干断层扫描的不同类型糖尿病性黄斑水肿对康柏西普的治疗反应[J]. 南方医科大学学报, 2021, 41(10):1501-1508.
	Zhang Y, Yao J, Quan Y L, et al. Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography[J]. J South Med Univ, 2021, 41(10):1501-1508. doi:10.12122/j.issn.1673-4254.2021.10.08.
[25]	Zhou Z H, Zhao L, Wang Y L, et al. Predictive impact of serous retinal detachment in refractory diabetic macular edema[J]. BMC Ophthalmol, 2025, 25(1):177. doi:10.1186/s12886-025-03993-1.
[26]	Sharma S, Karki P, Joshi S N, et al. Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab:a short-term study[J]. Ther Adv Ophthalmol, 2022, 14:25158414221074519. doi:10.1177/25158414221074519.
[27]	Wang Y, Li F, Hao M, et al. Predictive value of hyperreflective foci for anti-VEGF therapeutic outcomes in different subtypes of diabetic macular edema: a retrospective analysis[J]. Front Endocrinol(Lausanne), 2025, 16:1648828. doi:10.3389/fendo.2025.1648828.
[28]	Sonoda S, Sakamoto T, Yamashita T, et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema[J]. Retina, 2014, 34(4):741-748. doi:10.1097/IAE.0b013e3182a48917.
[29]	Sepah Y J, Do D V, Mesquida M, et al. Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy[J]. Eye(Lond), 2024, 38(9):1755-1761. doi:10.1038/s41433-024-03015-2.
[30]	Yao J, Huang W, Gao L, et al. Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography:A network meta-analysis[J]. PLoS One, 2024, 19(6):e0304283. doi:10.1371/journal.pone.0304283.
[31]	Chou J F, Wu J S, Chen Y L, et al. Modified early intensive and treat-and-extend regimen of anti-vascular endothelial growth factor for diabetic macular edema in Taiwan[J]. Sci Rep, 2023, 13(1):19349. doi:10.1038/s41598-023-43931-z.
[32]	Midena E, Torresin T, Schiavon S, et al. The disorganization of retinal inner layers is correlated to müller cells impairment in diabetic macular edema:An imaging and omics study[J]. Int J Mol Sci, 2023, 24(11):9607. doi:10.3390/ijms24119607.
[33]	Lu W, Xiao K, Zhang X, et al. A machine learning model for predicting anatomical response to anti-VEGF therapy in diabetic macular edema[J]. Front Cell Dev Biol, 2025, 13:1603958. doi:10.3389/fcell.2025.1603958.
[34]	Wall K, Arend L P, Von Der Emde L, et al. Characterization of the disorganization of the inner retinal layers in diabetics using increased axial resolution optical coherence tomography[J]. Transl Vis Sci Technol, 2025, 14(1):12. doi:10.1167/tvst.14.1.12.
[35]	Nicholson L, Ramu J, Triantafyllopoulou I, et al. Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy[J]. Clin Exp Ophthalmol, 2015, 43(8):735-741. doi:10.1111/ceo.12557.
[36]	Jatoi A. Association between integrity of foveal photoreceptors and ultimate visual outcome in neovascular age-related macular degeneration[J]. Vestn Oftalmol, 2025, 141(1):32-36. doi:10.17116/oftalma202514101132.
[37]	Hsieh T C, Deng G H, Chang Y C, et al. A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment[J]. Front Endocrinol(Lausanne), 2023, 14:1108097. doi:10.3389/fendo.2023.1108097.
[38]	Maheshwary A S, Oster S F, Yuson R M, et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema[J]. Am J Ophthalmol, 2010, 150(1):63-67.e1. doi:10.1016/j.ajo.2010.01.039.
[39]	Mat Nor M N, Guo C X, Green C R, et al. Hyper-reflective dots in optical coherence tomography imaging and inflammation markers in diabetic retinopathy[J]. J Anat, 2023, 243(4):697-705. doi:10.1111/joa.13889.
[40]	Maguire M, Laidlaw D, Davies N, et al. The impact of vitreo-macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262(11):3501-3508. doi:10.1007/s00417-024-06518-6.
[41]	Wang Q, Wang C, Su Y, et al. Topographic correlation of microperimetry with foveal microstructure characteristics in idiopathic epiretinal membrane patients with an ectopic inner foveal layer[J]. Eye Vis(Lond), 2025, 12(1):4. doi:10.1186/s40662-024-00419-9.
[42]	Liu D, Chen X, Cai S. Inhibition of retinal neovascularization by Dendrobium polysaccharides:a review[J]. Front Pharmacol, 2025, 16:1584553. doi:10.3389/fphar.2025.1584553.
[43]	Watanabe A, Takashina H, Nakano T. Effect of microaneurysms on the anti-VEGF treatment for diabetic macular edema:A retrospective cross-sectional study[J]. Medicine(Baltimore), 2023, 102(44):e35888. doi:10.1097/MD.0000000000035888.
[44]	Allingham M J, Mukherjee D, Lally E B, et al. A quantitative approach to predict differential effects of anti-VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema:A pilot study[J]. Transl Vis Sci Technol, 2017, 6(2):7. doi:10.1167/tvst.6.2.7.
[45]	Rana V, Agarwal A, Arora A, et al. Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema[J]. Indian J Ophthalmol, 2024, 72(Suppl 1):S16-S21. doi:10.4103/IJO.IJO_893_23.
[46]	Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema:A descriptive review[J]. Medicina(Kaunas), 2023, 59(3):435. doi:10.3390/medicina59030435.